Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Oragenics Inc
(NY:
OGEN
)
0.9440
+0.0140 (+1.51%)
Official Closing Price
Updated: 8:00 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Oragenics Inc
< Previous
1
2
Next >
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Completes Manufacture, Filling of Intranasal Device for Use in Upcoming Clinical Trial
Today 11:58 EDT
Via
Investor Brand Network
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Reports on Status of Lead Drug Candidate Designed to Treat Concussion
August 19, 2024
Via
Investor Brand Network
Exposures
Product Safety
“Explosive Growth Stocks: Innovations, Strategy, Earners Unlock Prime Potential CXAI, OGEN, PRSO, INBS, KAVL”
August 14, 2024
Via
AB Newswire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032
August 09, 2024
EQNX::TICKER_START (NYSE:OGEN),(NYSE:ABT),(NASDAQ:BIIB),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END
Via
FinancialNewsMedia
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
April 19, 2024
From
Oragenics, Inc.
Via
Business Wire
Oragenics, Inc. Files 10K and Provides Company Update
April 01, 2024
From
Oragenics, Inc.
Via
Business Wire
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion
March 18, 2024
From
Oragenics, Inc.
Via
Business Wire
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion
March 05, 2024
From
Oragenics, Inc.
Via
Business Wire
Oragenics Announces Closing of Public Offering
March 01, 2024
From
Oragenics, Inc.
Via
Business Wire
Oragenics Announces Pricing of Public Offering
February 27, 2024
From
Oragenics, Inc.
Via
Business Wire
Oragenics Announces Proposed Public Offering
February 27, 2024
From
Oragenics, Inc.
Via
Business Wire
Oragenics, Inc. Announces Leadership Transition
February 12, 2024
From
Oragenics, Inc.
Via
Business Wire
Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement
February 07, 2024
From
Oragenics, Inc.
Via
Business Wire
Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion
February 05, 2024
From
Oragenics, Inc.
Via
Business Wire
Oragenics Announces Termination of At-The-Market Offering Program
January 23, 2024
From
Oragenics, Inc.
Via
Business Wire
Oragenics Completes Acquisition of Odyssey Health’s Neurological Assets
January 02, 2024
From
Oragenics, Inc.
Via
Business Wire
Oragenics Issues Update to Shareholders
November 02, 2023
From
Oragenics
Via
Business Wire
Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of Directors
October 18, 2023
From
Oragenics, Inc.
Via
Business Wire
Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate
October 05, 2023
From
Oragenics, Inc.
Via
Business Wire
Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy Assets
September 29, 2023
From
Oragenics, Inc.
Via
Business Wire
Oragenics, Inc. Announces Private Placement
August 07, 2023
From
Oragenics, Inc.
Via
Business Wire
Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDM
June 05, 2023
From
Oragenics, Inc.
Via
Business Wire
Oragenics to Participate in the World Vaccine Congress Washington
March 29, 2023
From
Oragenics, Inc.
Via
Business Wire
Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VRE
March 14, 2023
From
Oragenics, Inc.
Via
Business Wire
Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership Team
March 08, 2023
From
Oragenics, Inc.
Via
Business Wire
Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine Candidate
March 01, 2023
From
Oragenics, Inc.
Via
Business Wire
Oragenics, Inc. Regains Compliance with NYSE American
February 03, 2023
From
Oragenics, Inc.
Via
Business Wire
Oragenics, Inc. Discloses One-for-Sixty Reverse Stock Split
December 23, 2022
From
Oragenics, Inc.
Via
Business Wire
Oragenics Reports Favorable Toxicology Results for its COVID-19 Intranasal Vaccine Candidate
December 22, 2022
From
Oragenics, Inc.
Via
Business Wire
Oragenics, Inc. Receives NYSE American Notice
December 20, 2022
From
Oragenics, Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.